Therapeutic use of fractionated total body and subtotal body irradiation.
Ninety-one patients were treated using fractionated subtotal body (STBI) or total body irradiation (TBI). These patients had generalized lymphomas, Hodgkin's disease, leukemias, myelomas, seminomas, or oat-cell carcinomas. Subtotal body irradiation is delivered to the entire body, except for the skull and extremities. It was expected that a significantly higher radiation dose could be administered with STBI than with TBI. STBI was given when there was a reasonable likelihood that malignancy did not involve the shielded volumes. A five- to ten-fold increase in tolerance for STBI was demonstrated. Many of these patients have had long-term (up to 17 year--?permanent) remissions. There is little or no treatment-induced symptomatology, and no "sanctuary sites." STBI and TBI are useful therapeutic modalities for many of these malignancies.
D000328:Adult; D000368:Aged; D004407:Dysgerminoma / Q000532:radiotherapy; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007958:Leukocyte Count; D008223:Lymphoma / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000532:radiotherapy*; D011379:Prognosis; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy / Q000379:methods*; D013154:Spleen / Q000528:radiation effects
D006454:Hemoglobins